Pharmaceuticals, Therapeutics And A Retailer On The Move Thursday Morning

BIND Therapeutics Inc BIND +42% - Provided clinical update for BIND-014.

Biodel Inc BIOD +38% - Reported positive preliminary results from Phase 2a clinical trial of BIOD-531.

Neurocrine Biosciences, Inc. NBIX +27% - Announced positive Phase 3 study results in cooperation with AbbVie.

NephroGenex Inc NRX +17% - The company received positive advice from the European Medicines Agency Regarding its Phase 3 program with Pyridorin.

Protalix Bio Therapeutics Inc. PLX +11% - Announced interim efficacy for PRX-102 trial.

Amicus Therapeutics, Inc. FOLD +10% - Reported additional favorable data on cardiac endpoint.

Aeropostale Inc ARO +6% - Raised Q4 EPS guidance.

Infinity Pharmaceuticals Inc. INFI -13% - Reported that its Phase 2 study of Duvelisib did not meet primary endpoint.

GW Pharmaceuticals PLC ADR GWPH -3% - Announced negative results from Sativex Phase 3 cancer pain trials.

Alexion Pharmaceuticals, Inc. ALXN -4% - Late Wednesday, the company provided an update on Phase 2 clinical trial with Eculizumab.

AmTrust Financial Services Inc AFSI - 4.7% - Announced a three million share offering.

Posted In: NewsPre-Market OutlookMovers
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...